Search results
Conduction System Pacing: A Fresh Look
Author(s):
Óscar Cano
,
Marek Jastrzębski
,
Pugazhendhi Vijayaraman
Start date:
Nov 13, 2024
Broadcast
Added:
1 year ago
In this week's episode of Parallax, host Dr Ankur Kalra engages in a thought-provoking discussion with Dr Stephen Smith, a pioneer in electrocardiography and myocardial infarction diagnosis. They delve into the groundbreaking OMI/NOMI paradigm (Occlusion MI vs Non-Occlusion MI), challenging the traditional STEMI vs non-STEMI terminology that has long been the cornerstone of acute coronary…
View more
Peter Block
Job title: Director of the Structural Heart Disease Program
Author
Author(s):
Parth Visrodia
,
Aniket S Rali
,
Gabriel Hernandez
,
et al
Added:
3 weeks ago
Alan Block
Job title: Podiatric Surgeon
Author
Kelley Branch
Research Area(s) / Expertise:
Job title: Associate Professor & Director of Cardiovascular Clinical Trials
Author
Iron Deficiency in LVAD Patients
Author(s):
William Herrik Nielsen
,
Finn Gustafsson
Added:
1 year ago
Article
Author(s):
Alexander Fanaroff
Added:
2 years ago
Stay up-to-date with the latest data in cardiovascular science with the help of renowned experts and emerging voices who offer concise summaries, in-depth discussions, and critical reviews to keep you informed.In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. With their keen awareness of…
View more
Author(s):
Anna Meta Dyrvig Kristensen
Added:
1 day ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled…
View more
Added:
2 months ago
Source:
Radcliffe Cardiology
The US Food and Drug Administration (FDA) has approved the non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia, Bayer). The new indication is for adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40% to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits.¹ The…
View more
